Alkermes News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

15.03.10	Amylin, Lilly and Alkermes Receive Complete Response Letter from FDA for exenatide Once Weekly Submission (Businesswire)
03.12.09	Alkermes Licenses Technology Platform for Long-Acting Fusion Proteins from Acceleron Pharma (Businesswire)
11.09.09	Alkermes Chairman Richard Pops to Resume Role of CEO (Businesswire)
20.07.09	Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus® in Head-to-Head DURATION-3 Study (Businesswire)
02.06.09	Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Investor Conferences (Businesswire)
09.01.09	Alkermes Announces Initiation of First Clinical Study for a Four-Week Long-Acting Injectable Formulation of Risperidone (Businesswire)
07.01.09	Alkermes’ Corporate Presentation to be Webcast at JPMorgan Annual Healthcare Conference (Businesswire)
01.12.08	Alkermes Regains Full Commercialization Rights to VIVITROL® in US (Businesswire)
06.11.08	Alkermes Announces Second Quarter Fiscal 2009 Results (Businesswire)
19.03.08	Alkermes Announces Restructuring (Businesswire)
07.02.08	Alkermes Announces Third Quarter Fiscal 2008 Results (Businesswire)
07.01.08	Alkermes Announces Agreement for the Commercialization of VIVITROL in Russia/CIS (Businesswire)
05.10.06	Alkermes and Rensselaer Polytechnic Institute Announce Exclusive Licensing Agreement for Novel Opioid Receptor Compounds (Businesswire)
03.10.06	Alkermes Expands Addiction Franchise to Include Development Program for Oral Products (Businesswire)
16.02.05	BIO CEO and Investor Conference to Webcast Alkermes' Corporate Presen (Businesswire)
03.02.05	Alkermes Announces Placement of $170 Million in Non-Recourse Notes Sec (Businesswire)
01.02.05	Alkermes to Host Conference Call to Discuss Financial Results for Thir (Businesswire)
20.01.05	Piper Jaffray Health Care Conference to Webcast Alkermes' Corporate P (Businesswire)
11.01.05	Alkermes to Expand Production Capacity for Risperdal Consta (Businesswire)
05.01.05	JP Morgan Annual Healthcare Conference to Webcast Alkermes' Corporate (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Kuehne+Nagel Int	210.40	0.00 %	K V
Novartis	96.17	0.00 %	K V
Sonova Hldg	298.70	-0.27 %	K V
Logitech Intl	93.84	-0.32 %	K V
Swisscom	497.40	-0.32 %	K V
Part Grp Hldg	1’390.00	-1.73 %	K V
Swiss Re	139.85	-1.96 %	K V
Geberit	523.80	-1.98 %	K V
Sika	234.00	-2.38 %	K V
Holcim	96.02	-3.85 %	K V